SG169224A1 - Method for treatment of tumors using nordihydrogualaretic acid derivatives - Google Patents

Method for treatment of tumors using nordihydrogualaretic acid derivatives

Info

Publication number
SG169224A1
SG169224A1 SG200507965-2A SG2005079652A SG169224A1 SG 169224 A1 SG169224 A1 SG 169224A1 SG 2005079652 A SG2005079652 A SG 2005079652A SG 169224 A1 SG169224 A1 SG 169224A1
Authority
SG
Singapore
Prior art keywords
tumors
treatment
acid derivatives
nordihydrogualaretic
nordihydrogualaretic acid
Prior art date
Application number
SG200507965-2A
Other languages
English (en)
Inventor
Ru Chih C Huang
Jonathan D Heller
Chih-Chuan Chang
Original Assignee
Univ Johns Hopkins
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Johns Hopkins filed Critical Univ Johns Hopkins
Publication of SG169224A1 publication Critical patent/SG169224A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/225—Polycarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/417—Imidazole-alkylamines, e.g. histamine, phentolamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Emergency Medicine (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
SG200507965-2A 2001-05-09 2002-05-08 Method for treatment of tumors using nordihydrogualaretic acid derivatives SG169224A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/851,425 US6608108B2 (en) 1999-10-15 2001-05-09 Method for treatment of tumors using nordihydroguaiaretic acid derivatives

Publications (1)

Publication Number Publication Date
SG169224A1 true SG169224A1 (en) 2011-03-30

Family

ID=25310742

Family Applications (1)

Application Number Title Priority Date Filing Date
SG200507965-2A SG169224A1 (en) 2001-05-09 2002-05-08 Method for treatment of tumors using nordihydrogualaretic acid derivatives

Country Status (8)

Country Link
US (3) US6608108B2 (https=)
EP (1) EP1392293B1 (https=)
JP (2) JP2004534025A (https=)
CN (1) CN1525857B (https=)
AU (1) AU2002311890C1 (https=)
CA (1) CA2447045A1 (https=)
SG (1) SG169224A1 (https=)
WO (1) WO2002089795A1 (https=)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6365787B1 (en) * 1994-09-30 2002-04-02 The Johns Hopkins University Compounds for the suppression of HIV TAT transactivation
US6608108B2 (en) * 1999-10-15 2003-08-19 Johns Hopkins University Method for treatment of tumors using nordihydroguaiaretic acid derivatives
US20060141029A1 (en) * 2003-05-20 2006-06-29 Erimos Pharmaceuticals Llc Methods and compositions for delivery of catecholic butanes for treatment of diseases
US7728036B2 (en) * 2003-05-20 2010-06-01 Erimos Pharmaceuticals, Llc Methods for delivery of catecholic butanes for treatment of tumors
WO2004112695A2 (en) * 2003-05-20 2004-12-29 Erimos Pharmaceutical Llc Methods and compositions for delivery of catecholic butanes for treatment of obesity
JP4579911B2 (ja) 2003-06-03 2010-11-10 アイシス・ファーマシューティカルズ・インコーポレイテッド スルビビン発現の調節
US20060019972A1 (en) * 2004-04-27 2006-01-26 California Institute Of Technology Methods of treating cancer by inhibiting histone gene expression
CN100440843C (zh) * 2004-05-12 2008-12-03 华为技术有限公司 一种环网及其业务实现方法
US8440648B2 (en) * 2004-07-20 2013-05-14 Erimos Pharmaceuticals Llc Methods and compositions for treatment of intraepithelial neoplasia
MX2007007624A (es) * 2004-12-22 2007-08-03 Gillette Co Reduccion del crecimiento del pelo con inhibidores de survivina.
CN101150955B (zh) * 2005-01-27 2013-04-17 埃里莫斯医药品有限公司 递送包括ndga化合物的儿茶酚丁烷的口服制剂
AU2006208108A1 (en) * 2005-01-27 2006-08-03 Erimos Pharmaceuticals Llc Oral formulations for delivery of catecholic butanes including NDGA compounds
US20060276423A1 (en) * 2005-04-18 2006-12-07 Rachel Altura Survivin-directed RNA interference-compositions and methods
US8367126B2 (en) 2005-09-27 2013-02-05 University Of Kentucky Research Foundation Berry preparations and extracts
CA2622286A1 (en) * 2005-09-27 2007-04-05 University Of Kentucky Research Foundation Anti-inflammatory composition comprising berry extract
EP1996174A2 (en) * 2006-02-23 2008-12-03 Erimos Pharmaceuticals LLC Methods of treating influenza viral infections
CA2661274A1 (en) * 2006-08-29 2008-03-06 University Of Kentucky Research Foundation Compositions and methods for oral cancer chemoprevention using berry preparations and extracts
US9067875B2 (en) 2006-10-02 2015-06-30 Erimos Pharmaceuticals Llc Tetra-substituted NDGA derivatives via ether bonds and carbamate bonds and their synthesis and pharmaceutical use
CN101547689B (zh) * 2006-10-02 2014-02-26 埃里莫斯医药品有限公司 通过醚键和氨基甲酸酯键四取代的ndga衍生物、它们的合成方法和药学用途
US20100093872A1 (en) * 2008-10-15 2010-04-15 Erimos Pharmaceuticals Llc Stable aqueous formulations of water insoluble or poorly soluble drugs
CN101690829B (zh) * 2009-08-31 2013-09-18 中国科学院上海硅酸盐研究所 一种可再细胞化的生物瓣瓣膜材料的制备方法
WO2011030329A1 (en) 2009-09-10 2011-03-17 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Method of treating tumors
MX2013008833A (es) 2011-02-02 2013-12-06 Amgen Inc Metodos y composiciones relacionadas con la inhibicion de receptor del factor de crecimiento similar a la insulina 1 (igf-1r).
US10342767B2 (en) 2011-04-21 2019-07-09 Children's Hospital Medical Center Therapy for kinase-dependent malignancies
EP2699237A4 (en) * 2011-04-21 2014-11-12 Childrens Hosp Medical Center THERAPY FOR LEUKEMIA
WO2013071056A2 (en) 2011-11-11 2013-05-16 Duke University Combination drug therapy for the treatment of solid tumors
US8980259B2 (en) 2012-07-20 2015-03-17 Novartis Ag Combination therapy
CN112472699A (zh) 2013-07-26 2021-03-12 种族肿瘤学公司 改善比生群及衍生物的治疗益处的组合方法
IL256242B2 (en) 2015-06-22 2024-09-01 Janssen Biotech Inc Combination therapies for heme malignancies with anti-cd38 antibodies and survivin inhibitors
WO2017129763A1 (en) 2016-01-28 2017-08-03 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of signet ring cell gastric cancer
MX391317B (es) 2017-02-17 2025-03-21 Promotora Tecnica Ind S A De C V Composicion mejorada a base de acido norhidroguayaretico.
WO2021108601A1 (en) 2019-11-25 2021-06-03 The Johns Hopkins University Formulations of terameprocol and temozolomide and their use in stimulation of humoral immunity in tumors

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988001509A1 (en) * 1986-08-25 1988-03-10 Chemex Pharmaceuticals, Inc. Pharmacologically active compositions of catecholic butanes with zinc
US4774229A (en) * 1982-04-05 1988-09-27 Chemex Pharmaceuticals, Inc. Modification of plant extracts from zygophyllaceae and pharmaceutical use therefor
EP0297733A2 (en) * 1987-06-03 1989-01-04 Block Drug Company, Inc. Pharmaceutical compositions comprising catecholic butanes
WO2001028494A2 (en) * 1999-10-15 2001-04-26 Johns Hopkins University Nordihydroguaiaretic derivatives for use in treatment of tumors

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5276060A (en) * 1979-06-19 1994-01-04 Block/Chemex, G.P. Methods of treating tumors with compositions of catecholic butanes
DE3009542A1 (de) 1980-03-13 1981-09-24 Henkel KGaA, 4000 Düsseldorf Desodorierende kosmetische zusammensetzungen
US4708964A (en) * 1984-02-09 1987-11-24 Chemex Pharmaceuticals Lipoxygenase inhibitors
US4880637A (en) 1985-02-11 1989-11-14 Chemex Pharmaceuticals, Inc. Compositions of catecholic butanes with zinc
US5559149A (en) 1990-01-29 1996-09-24 Johnson & Johnson Consumer Products, Inc. Skin care compositions containing retinoids
US5646186A (en) 1994-05-17 1997-07-08 Johnson & Johnson Consumer Products, Inc. Retinoid composition
US5409690A (en) * 1993-06-23 1995-04-25 Chemex Pharmaceuticals, Inc. Treatment of multidrug resistant diseases in cancer cell by potentiating with masoprocol
US6365787B1 (en) 1994-09-30 2002-04-02 The Johns Hopkins University Compounds for the suppression of HIV TAT transactivation
US6071949A (en) * 1995-03-14 2000-06-06 The United States Of America As Represented By The Department Of Health And Human Services Use of lipoxygenase inhibitors as anti-cancer therapeutic and intervention agents
US5837252A (en) 1996-07-01 1998-11-17 Larreacorp, Ltd. Nontoxic extract of Larrea tridentata and method of making same
US5827898A (en) 1996-10-07 1998-10-27 Shaman Pharmaceuticals, Inc. Use of bisphenolic compounds to treat type II diabetes
ATE414149T1 (de) * 1996-11-20 2008-11-15 Univ Yale Survivin, ein protein das zelluläre apoptosis hemmt, und dessen modulation
US6077709A (en) * 1998-09-29 2000-06-20 Isis Pharmaceuticals Inc. Antisense modulation of Survivin expression
US6608108B2 (en) * 1999-10-15 2003-08-19 Johns Hopkins University Method for treatment of tumors using nordihydroguaiaretic acid derivatives

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4774229A (en) * 1982-04-05 1988-09-27 Chemex Pharmaceuticals, Inc. Modification of plant extracts from zygophyllaceae and pharmaceutical use therefor
WO1988001509A1 (en) * 1986-08-25 1988-03-10 Chemex Pharmaceuticals, Inc. Pharmacologically active compositions of catecholic butanes with zinc
EP0297733A2 (en) * 1987-06-03 1989-01-04 Block Drug Company, Inc. Pharmaceutical compositions comprising catecholic butanes
WO2001028494A2 (en) * 1999-10-15 2001-04-26 Johns Hopkins University Nordihydroguaiaretic derivatives for use in treatment of tumors

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
NE EXPRESSION BY NORDIHYDROGUAIARETIC ACID PLANT LIGNAN DERIVATIVIES, US *

Also Published As

Publication number Publication date
CN1525857A (zh) 2004-09-01
US20030171416A1 (en) 2003-09-11
AU2002311890B2 (en) 2007-07-26
US20020065310A1 (en) 2002-05-30
JP2009242438A (ja) 2009-10-22
EP1392293B1 (en) 2016-10-26
CN1525857B (zh) 2013-06-12
JP2004534025A (ja) 2004-11-11
EP1392293A1 (en) 2004-03-03
CA2447045A1 (en) 2002-11-14
US8318815B2 (en) 2012-11-27
US6777444B2 (en) 2004-08-17
US6608108B2 (en) 2003-08-19
US20040127562A1 (en) 2004-07-01
WO2002089795A1 (en) 2002-11-14
AU2002311890C1 (en) 2008-05-15
EP1392293A4 (en) 2005-05-25

Similar Documents

Publication Publication Date Title
SG169224A1 (en) Method for treatment of tumors using nordihydrogualaretic acid derivatives
YU21702A (sh) Supstituisani indoli za moduliranje nfkb aktivnosti
MY151032A (en) Treatment of tnf? related disorders
MXPA05013224A (es) Piridinilcarbamatos como inhibidores de lipasa sensible a hormonas.
EA200200990A1 (ru) Ингибиторы фосфатидилинозитол-3-киназы дельта человека
MXPA05007822A (es) Terapia de combinacion para tratar trastornos de la deficiencia de proteinas.
MY140767A (en) Compounds, methods and compositions
MXPA06000302A (es) Derivados de pirazolil-indol activos como inhibidores de cinasa, procedimientos para su preparacion y composiciones farmaceuticas que los comprenden.
TW200510306A (en) Novel hydroxyindoles, their use as inhibitors of phosphodiesterase 4, and processes for preparing them
DK1373215T3 (da) Gelanamycinderivater egnet til behandling af cancer
JO2764B1 (en) Indole derivatives or benzimidazole derivatives to modify the enzyme AKP kinase
BRPI0413427A (pt) derivados de piridilpirrol ativos como inibidores da cinase
NO20071426L (no) Kreft kombinasjonsbehandling omfattende AZD2171 og Imatinib
MY140169A (en) Compounds, compositions, and methods
MX2025005941A (es) Moduladores de la actividad tnf-\03b1
GB9815177D0 (en) Treatment of skin disorders
MX2024013020A (es) Compuestos de heteroarilo para el tratamiento del dolor
DE60121303D1 (de) Mittel, wie nikotinamide oder cadpr zur behandlung von hautkrankheiten
NO990433L (no) Nye forbindelser og blandinger for behandling av sykdommer i forbindelse med tryptase-aktivitet
WO2003024386A3 (en) Use of potent, selective and non toxic c-kit inhibitors for treating interstitial cystitis
CR20240514A (es) Compuestos de heteroarilo para el tratamiento del dolor
AU2838101A (en) Use of melatonin for treating androgenetic and diffuse alopecia
BRPI0413438A (pt) derivados de pirimidilpirrol ativos como inibidores de cinase
IL163951A (en) Heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them
AU2003252025A8 (en) Compounds, compositions, and methods